Welcome to our dedicated page for Bioharvest news (Ticker: BHST), a resource for investors and traders seeking the latest updates and insights on Bioharvest stock.
BioHarvest Sciences Inc. (NASDAQ: BHST) is a biotechnology company that describes itself as a leader in Botanical Synthesis, using its patented plant cell-based platform to grow active plant compounds without cultivating the whole plant. The BioHarvest news stream highlights how this technology underpins both its direct-to-consumer nutraceutical products and its contract development and manufacturing (CDMO) services.
Investors following BHST news can read about developments in the company’s VINIA brand, including capsules, hot beverages, daily chews, and VINIA Blood Flow Hydration, which the company presents as a hydration solution powered by the blood flow benefits of Piceid resveratrol. News items also cover subscriber trends, online channel performance, and the expansion of VINIA into broader health and wellness categories.
Another major theme in BioHarvest’s news is the evolution of its CDMO Services division. Company updates describe new customer contracts in pharmaceuticals, nutrition, fragrance, and nutraceuticals, such as a saffron-derived compound partnership with Saffron Tech and work on a plant-based fragrance compound. Releases also discuss milestones like producing plant-based exosomes at scale in a bioreactor and integrating AI-based tools into a second-generation Botanical Synthesis process.
Capital markets and regulatory announcements form a further part of the BHST news flow, including public offerings under a Form F-3 shelf registration, material change reports, and interim financial results filed on Form 6-K. Readers can use this page to monitor BioHarvest’s operational updates, technology progress, and financing activities in one place.
BioHarvest Sciences (NASDAQ: BHST) issued a year-end letter reporting an annualized revenue run rate exceeding US$36 million, gross margins above 60%, and a plan to reach adjusted EBITDA breakeven in the near term. The company reported >85,000 active VINIA users, >90% subscription purchase rate, and 10,000+ verified reviews at a 4.7/5 average rating.
Operational highlights include VINIA Blood Flow Hydration launched in-market, CDMO contract wins in May and October 2025 (including a 25% ownership stake in a saffron-derived compound), AI-enabled discovery services, and a planned 100-ton manufacturing footprint. BioHarvest raised approximately $30.8 million in 2025 to fund growth and manufacturing expansion.
BioHarvest (NASDAQ: BHST) was awarded a $1.6 million grant from the Israeli Innovation Authority under its Bio-Convergence program on December 18, 2025.
The non-dilutive, zero-interest loan will fund development of the company’s second-generation Botanical Synthesis™ platform, including AI tools for process optimization, larger bioreactors for higher-volume production, and expanded autonomous manufacturing to improve scalability and unit economics.
BioHarvest reports it is fully funded for current plans with approximately $25 million in cash; repayment of the IIA loan is contingent on predefined commercial milestones and expected to be paid from future project revenues.
BioHarvest Sciences (NASDAQ: BHST) on December 3, 2025 launched VINIA Blood Flow Hydration, a hydration stick-pack powered by VINIA's Piceid resveratrol and red-grape polyphenols entering the $13 billion U.S. electrolyte drink market. The formula delivers 23 mg red-grape polyphenols including 6 mg rapid-absorption Piceid resveratrol, plus naturally sourced electrolytes: 470 mg sodium, 190 mg potassium, and 80 mg magnesium per serving. The product is shipping nationwide via VINIA.com with free North America delivery, will appear on Amazon by end of December 2025, is Informed Sport tested, and is backed by a 90-day “Feel It or It’s Free” guarantee. Clinical support is cited from Vaisman et al., 2015.
BioHarvest Sciences (NASDAQ: BHST) reported third quarter 2025 results: revenue $9.1M, +39% YoY, gross profit $5.6M (61% margin), and a net loss of $2.5M or $0.14 per share. Management expects Q4 2025 revenue of $9.0–9.5M and adjusted EBITDA of ($0.6)–$0.0M.
Operational highlights include a VINIA user base >75,000, a VIP early adopter launch of VINIA Blood Flow Hydration (market rollout Dec 3), a breakthrough producing plant-based exosomes at scale, and a new CDMO customer (Saffron Tech) with BioHarvest retaining 25% ownership of the compound. The company strengthened its balance sheet via accelerated warrant exercises and debt conversions and a $19.9M institutional equity raise in November.
BioHarvest Sciences (NASDAQ: BHST) announced management will attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025 in New York.
CEO Ilan Sobel is scheduled for one-on-one investor meetings at the Sheraton New York Times Square. The company highlighted momentum in its consumer VINIA® capsule business, new product lines (VINIA® Daily Chews 2X Formula and VINIA® Blood Flow Hydration Solution), CDMO milestones including a plant-based exosome production breakthrough and a new saffron compound development contract, and the close of an upsized $19.9 million equity offering led by Craig-Hallum. Management cited a focus on delivering adjusted EBITDA breakeven in the near term. Registration is mandatory; meetings arranged via MZ Group at BHST@mzgroup.us.
BioHarvest Sciences (NASDAQ: BHST) closed an upsized underwritten public offering of 2,846,854 common shares at a public offering price of $7.00 per share, including 361,854 shares issued upon exercise of the underwriters' option. Gross proceeds were $19.9 million before underwriting discounts and offering expenses. Craig-Hallum served as sole managing underwriter.
The company said net proceeds will fund additional manufacturing expansion, R&D, marketing, debt reduction or refinancing, capital expenditures, and working capital. Management plans to provide updates on strategic initiatives during its third quarter earnings call on November 13, 2025.
BioHarvest Sciences (NASDAQ: BHST) priced an underwritten public offering of 2,485,000 common shares at $7.00 per share, for gross proceeds of about $17.4 million, before underwriting discounts and expenses.
The company granted the underwriters a 30-day option to buy up to 372,750 additional shares at the public price less the underwriting discount. BioHarvest expects to close the offering on or about November 10, 2025, with Craig-Hallum as sole managing underwriter.
Net proceeds are expected to be used for R&D, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes. The offering is made under a Form F-3 shelf registration declared effective on September 8, 2025.
BioHarvest (NASDAQ: BHST) announced on November 6, 2025 its intent to conduct an underwritten public offering of common stock, with Craig-Hallum as sole managing underwriter.
The company said it may grant the underwriter a 30-day option to buy up to an additional 15% of the shares. Proceeds are expected to be used for R&D, manufacturing, marketing, advancing the CDMO business unit, debt reduction or refinancing, capital expenditures, and general corporate purposes. The offering is subject to market conditions and filing of a preliminary prospectus supplement to the SEC.
BioHarvest Sciences (NASDAQ: BHST) will release third quarter 2025 financial results for the period ended September 30, 2025 after market close on Thursday, November 13, 2025. Management will host an investor conference call and webcast at 4:30 p.m. Eastern time on November 13 to discuss Q3 2025 results, provide a corporate update, and hold a Q&A session for telephone participants.
Call details: U.S./Canada dial-in 1-877-300-8521; international dial-in 1-412-317-6026; conference ID 6486821. A telephone playback will be available through Thursday, November 27, 2025 (U.S./Canada replay 1-844-512-2921; international 1-412-317-6671; replay PIN 10204225). A webcast and replay will be available via the company webcast link.
BioHarvest Sciences (NASDAQ: BHST) entered a strategic CDMO partnership with Saffron Tech to develop and commercialize saffron-derived compounds using BioHarvest's patented Botanical Synthesis platform.
Key terms: Saffron Tech will own 75% of developed compositions and IP, BioHarvest will retain 25%. BioHarvest expects Q3 2025 revenue ≈ $9.1M, adjusted EBITDA of ($0.7M) to ($0.4M), cash ≈ $11M as of Sept 30, 2025, and Q4 2025 guidance of $9.0–$9.5M revenue with adjusted EBITDA ($0.6M) to $0.0M. Management highlighted VINIA and CDMO growth and a VINIA BloodFlow Hydration launch on Nov 7, 2025.
FAQ
What is the current stock price of Bioharvest (BHST)?
What is the market cap of Bioharvest (BHST)?
